**Links for Module 20, SISCR 2017**

**Links for Session 2:**

[Dispenzieri A, Katzmann JA, Kyle RA, Larson DR, Therneau TM, Colby CL, Clark RJ, Mead GP, Kumar S, Melton III LJ, Rajkumar SV. Use of Nonclonal Serum Immunoglobulin Free Light Chains to Predict Overall Survival in the General Population. Mayo Clinic Proceedings. 2012 Jun;87(6):517–523.](http://www.sciencedirect.com/science/article/pii/S0025619612003886)

[Kyle RA. “Benign” Monoclonal Gammopathy—After 20 to 35 Years of Follow-Up. Mayo Clinic Proceedings. 1993 Jan 1;68(1):26–36.](http://www.sciencedirect.com/science/article/pii/S0025619612600159)

[Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE. Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer. New England Journal of Medicine. 2007 Dec 27;357(26):2666–2676.](http://dx.doi.org/10.1056/NEJMoa072113)

[Ashburner JM, Go AS, Chang Y, Fang MC, Fredman L, Applebaum KM, Singer DE. Influence of Competing Risks on Estimating the Expected Benefit of Warfarin in Individuals with Atrial Fibrillation Not Currently Taking Anticoagulants: The Anticoagulation and Risk Factors in Atrial Fibrillation Study. J Am Geriatr Soc. 2017 Jan 1;65(1):35–41.](http://onlinelibrary.wiley.com.offcampus.lib.washington.edu/doi/10.1111/jgs.14516/abstract)

[Noordzij M, Leffondré K, Stralen V, J K, Zoccali C, Dekker FW, Jager KJ. When do we need competing risks methods for survival analysis in nephrology? Nephrol Dial Transplant. 2013 Nov 1;28(11):2670–2677.](https://academic.oup.com/ndt/article/28/11/2670/1823847/When-do-we-need-competing-risks-methods-for)

**Links for Session 4:**

[Redelmeier DA, Singh SM. Survival in Academy Award Winning Actors and Actresses. Annals of Internal Medicine. 2001 May 15;134(10):955.](http://annals.org/article.aspx?doi=10.7326/0003-4819-134-10-200105150-00009)

[Söderberg-Nauclér C, Rahbar A, Stragliotto G. Survival in Patients with Glioblastoma Receiving Valganciclovir. New England Journal of Medicine. 2013 Sep 5;369(10):985–986.](http://dx.doi.org/10.1056/NEJMc1302145)

[Suissa S. Immortal time bias in observational studies of drug effects. Pharmacoepidem Drug Safe. 2007 Mar 1;16(3):241–249.](http://onlinelibrary.wiley.com/doi/10.1002/pds.1357/abstract)

[Rich JD, Cannon CP, Murphy SA, Qin J, Giugliano RP, Braunwald E. Prior Aspirin Use and Outcomes in Acute Coronary Syndromes. Journal of the American College of Cardiology. 2010 Oct 19;56(17):1376–1385.](http://www.sciencedirect.com/science/article/pii/S0735109710034522)

[Gruberg L, Weissman NJ, Waksman R, Fuchs S, Deible R, Pinnow EE, Ahmed LM, Kent KM, Pichard AD, Suddath WO, Satler LF, Lindsay J. The impact of obesity on the short-term andlong-term outcomes after percutaneous coronary intervention: the obesity paradox? Journal of the American College of Cardiology. 2002 Feb 20;39(4):578–584](http://www.sciencedirect.com/science/article/pii/S0735109701018022).

**Good Introductory Books on Survival Analysis:**

[Kleinbaum DG, Klein M. Survival Analysis [Internet]. New York, NY: Springer New York; 2012](http://link.springer.com/10.1007/978-1-4419-6646-9)

[Hosmer D., Lemeshow S., May S. Applied survival analysis: regression modeling of time-to-event data [Internet]. 2nd ed. Hoboken, N.J.: Wiley-Interscience; 2008](http://onlinelibrary.wiley.com.offcampus.lib.washington.edu/book/10.1002/9780470258019)